Sanofi Settles Patent Suit Over Copies of Gaucher-Treatment Drug

Sanofi’s Genzyme unit and The Regents of the University of Michigan, co-owners of a patent on the Gaucher-treatment drug Cerdelga, agreed to settle a lawsuit with closely held generic-drug makers Apotex and Aizant, the only remaining defendants in a consolidated case that was set for trial on Monday.

• All patent-related claims and counterclaims were dismissed with prejudice, but no details of the settlement were included in the dismissal orders issued Thursday in federal court in Wilmington, Delaware
• Patent covers eliglustat, Cerdelga’s active ingredient, and expires in June 2026: FDA Orange Book
• NOTE: Gaucher is a rare, inherited ...